Abstract
Soluble angiotensin-converting enzyme 2 (sACE2) could be a therapeutic option to treat coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes ACE2 receptors on cell surfaces to gain intracellular entry, making them an ideal target for therapy. High-affinity variants of sACE2, engineered using high-throughput mutagenesis, are capable of neutralizing COVID-19 infection as decoy receptors. These variants compete with native ACE2 present on cells by binding with spike (S) protein of SARS-CoV-2, making native ACE2 on cell surfaces available to convert angiotensin II to angiotensin-1,7, thus alleviating the exaggerated inflammatory response associated with COVID-19 infection. This article explores the use of sACE2 as potential therapy for COVID-19 infection.
Keywords: ARDS; COVID-19; SARS-CoV-2; lung injury; soluble ACE2.
【저자키워드】 COVID-19, SARS-CoV-2, ARDS, Lung injury, soluble ACE2., 【초록키워드】 coronavirus disease, severe acute respiratory syndrome coronavirus 2, Coronavirus disease 2019, ACE2, ARDS, coronavirus, therapy, variant, Infection, lung, ACE2 receptor, Lung injury, severe acute respiratory syndrome Coronavirus, angiotensin-converting enzyme 2, Protein, COVID-19 infection, ACE2 receptors, Neutralizing, receptors, respiratory, binding, Angiotensin II, soluble ACE2, Mutagenesis, angiotensin, therapeutic option, acute respiratory syndrome, acute respiratory syndrome coronavirus, treat, potential therapy, exaggerated inflammatory response, sACE2, Cell, with COVID-19, 【제목키워드】 ACE2,